您所在的位置: 首页 --> 导师团队 --> 邢晓芳

导师基本信息

  • 姓名:邢晓芳
  • 性别:
  • 民族:汉族
  • 科室:胃肠肿瘤转化研究实验室
  • 职称:研究员
  • 专业:肿瘤学
  • E-MAIL: xingxiaofang_817@163.com

学术论文 | 出版专著 | 奖励表彰 | 研究方向 | 专利 | 科研项目 | 招生计划

Tang XH#, Guo T#, Gao XY#, Wu XL, Xing XF*, Ji JF*, Li ZY*. Exosome-derived noncoding RNAs in gastric cancer: functions and clinical applications. Mol Cancer. 2021 Jul 30;20(1):99. doi: 10.1186/s12943-021-01396-6. PMID: 34330299; PMCID: PMC8323226.,Mol Cancer,20(1):99

Ma X#, Jia S#, Wang G#, Liang M, Guo T, Du H, Li S, Li X, Huangfu L, Guo J*, Xing X*, Ji J*. TRIM28 promotes the escape of gastric cancer cells from immune surveillance by increasing PD-L1 abundance.,Signal Transduct Target Ther,8(1):246

Guo T#, Tang XH#, Gao XY, Zhou Y, Jin B, Deng ZQ, Hu Y, Xing XF*, Li ZY*, Ji JF*. A liquid biopsy signature of circulating exosome-derived mRNAs, miRNAs and lncRNAs predict therapeutic efficacy to neoadjuvant chemotherapy in patients with advanced gastric cancer. Mol Cancer. 2022 Dec 12;21(1):216. doi: 10.1186/s12943-022-01684-9. PMID: 36510184,Mol Cancer,21(1):216

Zhenhua Lu, Xiaohuan Tang,Xiaofang Xing*, Effect of multitarget faecal immunochemical testing on colorectal cancer screening strategies,LANCET ONCOL,25(6):e226

Song P#, Jiang Q#, Wu X, Bu L, Xie W, Wei W*, Xing X*, Guo J*. Palmitic acid and palmitoylation in cancer: Understanding, insights, and challenges.,Innovation,6(8):100918

Yang Du#, Meng Cai#, Xiaofang Xing#, Jiafu Ji, Ence Yang*, Jianmin Wu*. PINA 3.0: mining cancer interactome.,Nucleic Acids Research,2021; 49: D1351-D1357

Han J#, Nie M#, Chen C#, Cheng X, Guo T, Huangfu L, Li X, Du H, Xing X*, Ji J*. SDCBP-AS1 destabilizes β-catenin by regulating ubiquitination and SUMOylation of hnRNP K to suppress gastric tumorigenicity and metastasis. Cancer Commun (Lond). 2022 Nov;42(11):1141-1161. doi: 10.1002/cac2.12367. Epub 2022 Oct 9. PMID: 36209503; PMCID: PMC9648392.,Cancer Communications,42(11):1141-1161

Guo Ting#, Bai Yanhua#, Cheng XiaoJing, Han Haibo, Du Hong, Hu Ying, Jia Shuqin*, Xing Xiaofang*, Ji Jiafu*. Insulin gene enhancer protein 1 mediates glycolysis and tumorigenesis of gastric cancer through regulating glucose transporter 4.,Cancer Commun (Lond),2021; 41: 258-272.

Xueying Wang# ,Hui Hui#,Jing Han# ,Ting Guo#,Yiding Wang #,Lin Meng,Cong Chen ,Jie He,Xiaoyong Guo,Fuyu Zhong,Hong Du,Jie Tian,Xiaofang Xing,Yang Du ,Jiafu Ji. A CLDN18.2-Targeted Nanoplatform Manipulates Magnetic Hyperthermia Spatiotemporally for Synergistic Immunotherapy in Gastric Cancer,Adv Sci (Weinh),Online ahead of print.

Huangfu L#, Zhu H#, Wang G#, Chen J#, Wang Y, Fan B, Wang X, Yao Q, Guo T, Han J, Hu Y, Du H, Li X, Ji J*, Xing X*. The deubiquitinase USP15 drives malignant progression of gastric cancer through glucose metabolism remodeling.,J Exp Clin Cancer Res,43(1):235

Wang G#, Wang H#, Ji X#, Wang T, Zhang Y, Jiang W, Meng L, Wu HJ*, Xing X*, Ji J*. Intratumoral microbiome is associated with gastric cancer prognosis and therapy efficacy.,Gut Microbes,16(1):2369336

Xing X#, Shi J#, Jia Y#, Dou Y#, Li Z#, Dong B, Guo T, Cheng X, Li X, Du H, Hu Y, Jia S*, Zhang J*, Li Z*, Ji J*. Effect of neoadjuvant chemotherapy on the immune microenvironment in gastric cancer as determined by multiplex immunofluorescence and T cell receptor repertoire analysis.,J Immunother Cancer,10(3):e003984

Huangfu L#, He Q, Han J, Shi J, Li X, Cheng X, Guo T, Du H, Zhang W, Gao X, Luan F, Xing X*, Ji J*. MicroRNA-135b/CAMK2D Axis Contribute to Malignant Progression of Gastric Cancer through EMT Process Remodeling.,Int J Biol Sci,17(8):1940-1952

Jing Han#, Runjia Fu, Cong Chen, Xiaojing Cheng, Ting Guo, Longtao Huangfu, Xiaomei Li, Hong Du , Xiaofang Xing*, Jiafu Ji*. CXCL16 Promotes Gastric Cancer Tumorigenesis via ADAM10-Dependent CXCL16/CXCR6 Axis and Activates Akt and MAPK Signaling Pathways,Internatianal Journal of Biological Science,17(11):2841-2852.

Huanbo Zhu # , Longtao Huangfu # , Junbing Chen , Jiafu Ji* , Xiaofang Xing*.Exploring the potential of extrachromosomal DNA as a novel oncogenic driver.,Science China-Life Sciences,68(1):144-157

L. Huangfu#, X. Wang#, S. Tian, J. Chen, X. Wang, B. Fan, Q. Yao, G. Wang, C. Chen, J. Han, X. Xing* and J. Ji*, Piceatannol enhances beclin-1 activity to suppress tumor progression and its combination therapy strategy with everolimus in gastric cancer.,SCI CHINA LIFE SCI,66(2):298-312

Ziqian Deng#, Ting Guo#, Jiwang Bi, Gangjian Wang, Ying Hu, Hong Du, Yuan Zhou*, Shuqin Jia*, Xiaofang Xing* and Jiafu Ji*, Transcriptome profiling of patient-derived tumor xenografts suggests novel extracellular matrix-related signatures for gastric cancer prognosis prediction,Journal of Translational Medicine,(2023) 21:638

Longtao Huangfu#, Biao Fan#, Gangjian Wang, Xuejun Gan, Shanshan Tian, Qifei He, Qian Yao, Jinyao Shi, Xiaomei Li, Hong Du, Xiangyu Gao, Xiaofang Xing*, Jiafu Ji*.Novel prognostic marker LINC00205 promotes tumorigenesis and metastasis by competitively suppressing miRNA-26a in gastric cancer,Cell Death Discov,2022 Jan 10;8(1):5.

Li Ziyu#, Jia Yongning#, Zhu Honglin#, Xing Xiaofang#, Pang Fei, Shan Fei, Li Shuangxi, Wang Danhua, Zhao Fangping, Ma Tonghui, Wang Sizhen, Ji Jiaful. Tumor mutation burden is correlated with response and prognosis in microsatellite-stable (MSS) gastric cancer patients undergoing neoadjuvant chemotherapy.,Gastric Cancer,2021.

Wang Y#, Gan X#, Cheng X#, Jia Y#, Wang G, Tang X, Du H, Li X, Liu X, Xing X*, Ji J*, Li Z*. ABCC2 induces metabolic vulnerability and cellular ferroptosis via enhanced glutathione efflux in gastric cancer.,Clinical and Translational Medicine,14(8):e1754

Chen C#, Han J#, He Q, Yao Q, Wang X, Peng Z, Sun Y*, Ji J*, Xing X*. Tumor-infiltrating immune cell profiles and changes associate with additional trastuzumab in preoperative chemotherapy for patients with HER2-positive gastric cancer.,British Journal of Cancer,131(9):1463-1472

Ma Zhonghua, Gao Xiangyu, Shuai Y ou, Wu Xiaolong, Yan Yan, Xing Xiaofang*, Ji Jiafu*. EGR1-mediated linc01503 promotes cell cycle progression and tumorigenesis in gastric cancer.,Cell Proliferation,2021; 54: e12922.

Shi J#, Wu Z#, Wu X$, Huangfu L, Guo T, Cheng X, Han J, Li Z*, Xing X*, Ji J*. Characterization of glycometabolism and tumor immune microenvironment for predicting clinical outcomes in gastric cancer.,iScience,26(3):106214

Jia X#, Guo T*, Li Z#, Zhang M, Feng Y, Dong B, Li Z, Hu Y, Li Z, Xing X*, Jia S*, Ji J. Clinicopathological and Immunomicroenvironment Characteristics of Epstein-Barr Virus-Associated Gastric Cancer in a Chinese Population.,Front Oncol,10:586752

Wang G#, Ji X#, Wang H#, Tang X, Xing X*, Ji J*. PTPRD/PTPRT mutation correlates to treatment outcomes of immunotherapy and immune landscape in pan-cancers.,Chin J Cancer Res,35(3):316-330

Wang GJ#, Huangfu LT#, Gao XY, Gan XJ, Xing XF*, Ji JF*. A Novel Classification and Scoring Method Based on Immune-Related Transcription Factor Regulation Patterns in Gastric Cancer.,Front Oncol,12:887244

Yiding Wang#, Ting Guo#, Xiaofang Xing#, Xijuan Liu, Xuejun Gan, Yingai Li, Yan Liu, Fei Shan, Zhouqiao Wu, Jiafu Ji, Ziyu Li.The accumulation of myeloid-derived suppressor cells participates in abdominal infection-induced tumor progression through the PD-L1/PD-1 axis,Mol Oncol,Online ahead of print

Ma Z#, Gao X#, Shuai Y#, Xing X*, Ji J*. The m6A epitranscriptome opens a new charter in immune system logic.,Epigenetics,16(8):819-837

He Q#, Huangfu L#, Fan B#, Zhuang Q, He L, Li L, You W*, Xing X*. T-cells infiltration mediates the association between neutrophil/lymphocyte ratio and survival in gastric cancer.,Cancer Med.,12(15):15893-15902

Sun S#, Meng L#, Xing X#, Li N#, Song Q, Qiao D, Qu L, Liu C, An G, Li Z*, Shou C*, Lian S*. Anti-PRL-3 Monoclonal Antibody inhibits the Growth and Metastasis of colorectal adenocarcinoma.,J Cancer,14(13):2585-2595

Chen J#, Li L#, Huangfu L, Du H, Ji X*, Xing X*, Ji J. Death receptor 5 promotes tumor progression in gastric cancer.,FEBS Open Bio,13(12):2375-2388

Metabolomics and Precision Medicine, 参编, 施普林格·自 然出版集团, 2025.9

北京大学临床肿瘤学院指导教师组“良师益友”荣誉称号, 北京大学临床肿瘤学院指导教师组“良师益友”荣誉称号, 第1完成人, 北京大学临床肿瘤学院教育处, 2021.6

中华医学科技奖, 中华医学科技奖一等奖, 第5完成人, 中华医学会, 2024.1

一种化合物EK143的USP15蛋白酶HUBL区域的变构抑制剂与应用, 发明专利, 第2完成人, 国家知识产权局, 中国, 2025.7

血浆外泌体生物标志物在胃癌新辅助化疗敏感人群筛查或疗效预测中的应用, 发明专利, 第5完成人, 国家知识产权局, 中国, 2022.8

一种抗肿瘤药物研发用可过滤式微波反应器, 实用新型, 第2完成人, 国家知识产权局, 中国, 2022.8

一种抗肿瘤药物配药装置, 实用新型, 第2完成人, 国家知识产权局, 中国, 2022.8

CLDN18.2介导EMT引起胃癌耐药的分子机制及其单抗治疗价值探索, 课题负责人, 2022.1.1~2024.12.31, 北京市自然科学基金

BET Bromodomain 家族蛋白在胃癌中的作用机制及靶向治疗研究, 课题负责人, 2021.1.1~2021.12.31, 北京大学临床医学项目

TOPK激酶通过调控PDL1翻译稳态导致胃癌免疫逃逸的机制研究, 课题负责人, 2026.1.1~2029.12.31, 国家自然科学基金委

EB病毒相关肿瘤浸润B淋巴细胞表型在EB病毒相关胃癌微环境塑造及免疫治疗响应中的作用机制研究, 课题负责人, 2025.1.1~2027.12.31, 院内基金青年科研人才计划-导师科研经费奖励

SIRT1去乙酰化修饰Trim28/BRD4复合物逆转胃癌化疗耐药的机制研究及干预策略, 课题负责人, 2023.1.1~2026.12.31, 国家自然科学基金委

紫杉醇对胃癌中PDL1表达及免疫微环境的调控机制及联合治疗模式探索, 课题负责人, 2019.1.1~2022.12.31, 国家自然科学基金委

紫杉醇通过上调PDL1表达引起胃癌耐药的机制研究, 课题负责人, 2019.1.1~2021.12.31, 北京市医管局培育项目

紫杉醇对胃癌PDL1表达和免疫微环境的调控机制研究, 课题负责人, 2019.1.1~2020.12.31, 北京市医院管理局青年人才培养“青苗”计划

临床决策支持系统研发与全自动一体化系统临床应用评估, 参加者, 2022.11.30~2027.9.30, 国家重点研发计划

胃癌免疫联合治疗策略的开发与验证, 子课题负责人, 2024.12.31~2028.11.30, 癌症、心脑血管、呼吸和代谢性疾病防治研究国家科技重大专项

研究生招生计划
招生年度 招生专业 学位级别 学位类型 研究方向 选拔方式 操作
2026 肿瘤学 硕士 学术学位 肿瘤学 全国统考

社会任职

  • 常委
  • member of The International Cancer Genome Consortium

学习、工作经历

  • 2023.8.1~,北京大学肿瘤医院、胃肠肿瘤转化研究实验室副主任/研究员
  • 2023.3.1~2025.2.28,国家自然科学基金委员会、医学部七处流动项目主任
  • 2020.3.1~2023.7.31,北京大学肿瘤医院、胃肠肿瘤转化研究实验室副主任/副研究员
  • 2016.6.1~2017.9.30,美国哈佛大学丹娜法伯癌症研究所、生物信息学方向、访问学者
  • 2015.8.1~2020.2.29,北京大学肿瘤医院、副研究员